Investors with a lot of money to spend have taken a bearish stance on Reviva Pharmaceuticals RVPH.
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with RVPH, it often means somebody knows something is about to happen.
So how do we know what these investors just did?
Today, Benzinga's options scanner spotted 11 uncommon options trades for Reviva Pharmaceuticals.
This isn't normal.
The overall sentiment of these big-money traders is split between 9% bullish and 90%, bearish.
Out of all of the special options we uncovered, 8 are puts, for a total amount of $663,591, and 3 are calls, for a total amount of $83,209.
Projected Price Targets
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $2.0 to $5.0 for Reviva Pharmaceuticals during the past quarter.
Volume & Open Interest Development
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Reviva Pharmaceuticals's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Reviva Pharmaceuticals's whale activity within a strike price range from $2.0 to $5.0 in the last 30 days.
Reviva Pharmaceuticals Option Volume And Open Interest Over Last 30 Days
Noteworthy Options Activity:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| RVPH | PUT | SWEEP | BEARISH | 01/16/26 | $3.6 | $3.3 | $3.5 | $5.00 | $194.9K | 689 | 1.7K |
| RVPH | PUT | SWEEP | BEARISH | 01/16/26 | $3.6 | $3.1 | $3.6 | $5.00 | $122.4K | 689 | 774 |
| RVPH | PUT | SWEEP | BEARISH | 01/16/26 | $3.6 | $2.9 | $3.6 | $5.00 | $115.2K | 689 | 374 |
| RVPH | PUT | SWEEP | BEARISH | 01/16/26 | $3.5 | $3.1 | $3.5 | $5.00 | $76.6K | 689 | 2.0K |
| RVPH | PUT | SWEEP | BEARISH | 01/16/26 | $3.5 | $2.7 | $3.5 | $5.00 | $44.8K | 689 | 1.1K |
About Reviva Pharmaceuticals
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.
Where Is Reviva Pharmaceuticals Standing Right Now?
- With a volume of 2,226,838, the price of RVPH is up 4.52% at $1.85.
- RSI indicators hint that the underlying stock may be approaching overbought.
- Next earnings are expected to be released in 83 days.
What The Experts Say On Reviva Pharmaceuticals
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $9.666666666666666.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * An analyst from D. Boral Capital persists with their Buy rating on Reviva Pharmaceuticals, maintaining a target price of $15. * Reflecting concerns, an analyst from Roth MKM lowers its rating to Buy with a new price target of $7. * An analyst from Maxim Group has elevated its stance to Buy, setting a new price target at $7.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Reviva Pharmaceuticals with Benzinga Pro for real-time alerts.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
